Repeated radioembolization in advanced liver cancer.
90Y yttrium
Repeated radioembolization
liver cancer
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
5
11
2020
Statut:
ppublish
Résumé
To evaluate safety and clinical outcome of repeated transarterial Between 2009 and 2018, n=288 patients underwent TARE for treatment of malignant liver disease in a tertiary care hospital. This retrospective single center study analyzed the safety and outcome of patients (n=11/288) undergoing repeated resin microsphere TARE. Included patients suffered from hepatocellular carcinoma (n=3), colorectal cancer (n=2), breast cancer (n=2), intrahepatic cholangiocarcinoma (n=3), and neuroendocrine carcinoma (n=1). All patients had shown either partial response (n=9) or stable disease (n=2) after first TARE. Lab parameters, response assessed by the Response Evaluation Criteria in Solid Tumors (mRECIST/RECIST) at 3 months and overall survival was analyzed. Additionally, patients with repeated TARE were compared to a matched control group (n=56) with single TARE therapy. Kaplan Meier analysis was performed to analyze survival. Patients after repeated TARE showed similar increase in lab parameters as compared to their first TARE. No case of radioembolization induced liver disease was observed. While n=5/11 patients showed a partial response and n=4/11 patients a stable disease after repeated TARE, only n=2/11 patients suffered from progressive disease. Median overall survival was 20.9±11.9 months for the repeated TARE group while it was 5.9±16.2 months for the control group. Repeated
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate safety and clinical outcome of repeated transarterial
METHODS
METHODS
Between 2009 and 2018, n=288 patients underwent TARE for treatment of malignant liver disease in a tertiary care hospital. This retrospective single center study analyzed the safety and outcome of patients (n=11/288) undergoing repeated resin microsphere TARE. Included patients suffered from hepatocellular carcinoma (n=3), colorectal cancer (n=2), breast cancer (n=2), intrahepatic cholangiocarcinoma (n=3), and neuroendocrine carcinoma (n=1). All patients had shown either partial response (n=9) or stable disease (n=2) after first TARE. Lab parameters, response assessed by the Response Evaluation Criteria in Solid Tumors (mRECIST/RECIST) at 3 months and overall survival was analyzed. Additionally, patients with repeated TARE were compared to a matched control group (n=56) with single TARE therapy. Kaplan Meier analysis was performed to analyze survival.
RESULTS
RESULTS
Patients after repeated TARE showed similar increase in lab parameters as compared to their first TARE. No case of radioembolization induced liver disease was observed. While n=5/11 patients showed a partial response and n=4/11 patients a stable disease after repeated TARE, only n=2/11 patients suffered from progressive disease. Median overall survival was 20.9±11.9 months for the repeated TARE group while it was 5.9±16.2 months for the control group.
CONCLUSIONS
CONCLUSIONS
Repeated
Identifiants
pubmed: 33145274
doi: 10.21037/atm-20-2658
pii: atm-08-17-1055
pmc: PMC7575953
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1055Informations de copyright
2020 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-2658). KR, MW, MK report receiving lectureship compensations and/or proctoring fees by SIRTeX Medical Europe, outside the submitted work. The other authors have no conflicts of interest to declare.
Références
Ann Oncol. 2015 Sep;26 Suppl 5:v8-30
pubmed: 26314782
J Vasc Interv Radiol. 2019 Dec;30(12):1915-1923
pubmed: 31353191
Cancer Biol Med. 2014 Dec;11(4):217-36
pubmed: 25610708
Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1185-1193
pubmed: 28197686
Ann Oncol. 2016 Sep;27(suppl 5):v28-v37
pubmed: 27664259
Cancer Biother Radiopharm. 2019 May;34(4):231-237
pubmed: 30758985
World J Radiol. 2016 May 28;8(5):449-59
pubmed: 27247711
Cardiovasc Intervent Radiol. 2013 Oct;36(5):1320-8
pubmed: 23354961
Br J Cancer. 2016 Jul 26;115(3):297-302
pubmed: 27336601
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):319-32
pubmed: 25966431
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Vasc Interv Radiol. 2020 Mar;31(3):401-408.e1
pubmed: 31983593
Cardiovasc Intervent Radiol. 2012 Feb;35(1):105-16
pubmed: 21431970
J Med Imaging Radiat Oncol. 2013 Feb;57(1):72-80
pubmed: 23374558
Pharm Stat. 2011 Mar-Apr;10(2):150-61
pubmed: 20925139
J Hepatol. 2019 Dec;71(6):1164-1174
pubmed: 31421157
Clin Colorectal Cancer. 2018 Dec;17(4):e617-e629
pubmed: 30033117
Cardiovasc Intervent Radiol. 2017 Dec;40(12):1882-1890
pubmed: 28685382
J Nucl Med. 2014 Mar;55(3):360-6
pubmed: 24516256
Ann Oncol. 2012 Oct;23 Suppl 7:vii124-30
pubmed: 22997445
Clin Radiol. 2017 Aug;72(8):626-635
pubmed: 28258743
Lancet Oncol. 2017 Sep;18(9):1159-1171
pubmed: 28781171
Hepatology. 2018 Oct;68(4):1429-1440
pubmed: 29194711
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Eur J Cancer. 2013 Oct;49(15):3122-30
pubmed: 23777743